Immunosuppressants are predisposing factors in this context, and these were recommended as adjunctive therapies in severe COVID-19 patients as early as 2020 (dexamethasone) and 2021 (anti-IL-6) [43,44,45,46]. This evidence concerns the gene IL6 and COVID-19.